{"id":48153,"date":"2023-03-23T19:13:38","date_gmt":"2023-03-23T17:13:38","guid":{"rendered":"https:\/\/newserver.fyb.de\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/"},"modified":"2023-03-23T19:14:20","modified_gmt":"2023-03-23T17:14:20","slug":"bayern-kapital-invests-in-mbiomics-in-series-a-round","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/","title":{"rendered":"Bayern Kapital invests in mbiomics in Series A round"},"content":{"rendered":"

Landshut\/Munich \u2014 Bayern Kapi\u00adtal, one of the most expe\u00adri\u00aden\u00adced and active inves\u00adtors in the high-tech finan\u00adcing land\u00adscape, is inves\u00adt\u00ading in mbio\u00admics GmbH. The Munich-based company is a pioneer in the field of micro\u00adbiome biotech\u00adno\u00adlogy and is deve\u00adlo\u00adping the first gene\u00adra\u00adtion of effec\u00adtive micro\u00adbiome-based live thera\u00adpeu\u00adtics (LBT). In addi\u00adtion to Bayern Kapi\u00adtal, MIG Capi\u00adtal as lead inves\u00adtor as well as High-Tech Gr\u00fcn\u00adder\u00adfonds and other private inves\u00adtors parti\u00adci\u00adpa\u00adted in the first closing of the Series A round with a total volume of EUR 13 million. The closing of the funding round puts mbio\u00admics at the fore\u00adfront of the emer\u00adging field of synthe\u00adtic micro\u00adbial consor\u00adtia, which have the poten\u00adtial to revo\u00adlu\u00adtio\u00adnize the treat\u00adment of a wide range of dise\u00ada\u00adses, from cancer to inflamm\u00ada\u00adtory bowel disease.<\/strong><\/p>\n

Foun\u00added in Munich in 2020, mbio\u00admics GmbH focu\u00adses on the deve\u00adlo\u00adp\u00adment of the first gene\u00adra\u00adtion of effec\u00adtive bacte\u00adrial living thera\u00adpeu\u00adtics (LBT). The company is using its proprie\u00adtary, custom profil\u00ading plat\u00adform and compu\u00adta\u00adtio\u00adnal tech\u00adno\u00adlo\u00adgies to gene\u00adrate high-reso\u00adlu\u00adtion precis\u00adion data to modu\u00adlate the micro\u00adbiota, over\u00adco\u00adming current bott\u00adlen\u00adecks in LBT deve\u00adlo\u00adp\u00adment. The tech\u00adno\u00adlogy enables a better under\u00adstan\u00adding of the inter\u00adac\u00adtions between the gut micro\u00adbiome and the host, allo\u00adwing mbio\u00admics to deve\u00adlop more effec\u00adtive micro\u00adbial consor\u00adtia that can be deli\u00advered to pati\u00adents as precis\u00adion thera\u00adpies. In addi\u00adtion, mbio\u00admics\u2019 core tech\u00adno\u00adlogy impro\u00adves pati\u00adent selec\u00adtion and moni\u00adto\u00adring for clini\u00adcal trials, crea\u00adting a compe\u00adti\u00adtive advantage.<\/p>\n

\u201cThe micro\u00adbiome offers a rich source of new thera\u00adpeu\u00adtic oppor\u00adtu\u00adni\u00adties that have not yet been fully explo\u00adred. Our goal is to harness the power of the micro\u00adbiome to treat dise\u00ada\u00adses that are diffi\u00adcult to treat with conven\u00adtio\u00adnal approa\u00adches,\u201d explains Dr. Markus Rinecker, co-foun\u00adder and CMO of mbio\u00admics<\/strong>. \u201cOur outstan\u00adding R&D team has deli\u00advered a tech\u00adno\u00adlo\u00adgi\u00adcal proof-of-concept for our analy\u00adsis plat\u00adform in record time. With this tech\u00adno\u00adlogy, mbio\u00admics is uniquely posi\u00adtio\u00adned to under\u00adstand the modu\u00adla\u00adtion of the micro\u00adbiome and deve\u00adlop effec\u00adtive thera\u00adpies,\u201d added Johan\u00adnes B. Woehr\u00adstein, Ph.D., co-foun\u00adder and CTO<\/strong>.<\/p>\n

\u201cWe are very plea\u00adsed to have the support of such a pres\u00adti\u00adgious group of inves\u00adtors who share our vision of harnes\u00adsing the power of the gut micro\u00adbiome to deve\u00adlop targe\u00adted thera\u00adpies,\u201d said Laura Figulla, Ph.D., co-foun\u00adder and CEO of mbio\u00admics<\/strong>. \u201cThis funding will allow us to build our plat\u00adform, acce\u00adle\u00adrate the selec\u00adtion of our first lead product candi\u00adda\u00adtes, and inten\u00adsify rese\u00adarch acti\u00advi\u00adties with an eye toward clini\u00adcal validation.\u201d<\/p>\n

\u201cThe influence of the micro\u00adbiome on dise\u00ada\u00adses is curr\u00adently being rese\u00adar\u00adched in many ways,\u201d said Monika Steger <\/strong>(photo \u00a9 Bayern Kapi\u00adtal), mana\u00adging direc\u00adtor of Bayern Kapi\u00adtal<\/strong>. \u201cmbio\u00admics shows great poten\u00adtial in the deve\u00adlo\u00adp\u00adment of micro\u00adbiome-based thera\u00adpeu\u00adtics for support\u00adive inter\u00adven\u00adtion in various dise\u00ada\u00adses and can thus take rese\u00adarch a decisive step forward. We look forward to pursuing this path toge\u00adther with the company and an expe\u00adri\u00aden\u00adced and finan\u00adci\u00adally strong inves\u00adtor consortium.\u201d<\/p>\n

Dr. Matthias Kromayer, Mana\u00adging Part\u00adner of MIG Capi\u00adtal<\/strong>commen\u00adted: \u201cWe are plea\u00adsed to announce our invest\u00adment in mbio\u00admics and to support the company on its jour\u00adney to deve\u00adlop a powerful, inno\u00adva\u00adtive thera\u00adpeu\u00adtics plat\u00adform. The company\u2019s approach of combi\u00adning new tech\u00adno\u00adlo\u00adgies with cutting-edge micro\u00adbiome rese\u00adarch is ground\u00adbrea\u00adking and has the poten\u00adtial to signi\u00adfi\u00adcantly improve treat\u00adment outco\u00admes for pati\u00adents. We look forward to support\u00ading mbio\u00admics\u2019 ongo\u00ading rese\u00adarch towards clini\u00adcal development.\u201d<\/p>\n

\u201cIn the deve\u00adlo\u00adp\u00adment of \u201cLive Bacte\u00adrial Products\u201d, micro\u00adbiome profil\u00ading remains one of the major chal\u00adlenges. Mbio\u00admics has deve\u00adlo\u00adped a novel high-perfor\u00admance profil\u00ading plat\u00adform that addres\u00adses key bott\u00adlen\u00adecks in the deve\u00adlo\u00adp\u00adment of micro\u00adbiome-based thera\u00adpeu\u00adtic approa\u00adches using novel bacte\u00adrial consor\u00adtia. We are plea\u00adsed to invest in an excel\u00adlent team and an inno\u00adva\u00adtive tech\u00adno\u00adlogy toge\u00adther with strong co-inves\u00adtors,\u201d adds Dr. Jan Engels, Invest\u00adment Mana\u00adger at High-Tech Gr\u00fcn\u00adder\u00adfonds<\/strong>.<\/p>\n

About Bayern Kapital<\/strong>
\nBayern Kapi\u00adtal GmbH, based in Lands\u00adhut, is the venture\/growth capi\u00adtal company of the Free State of Bava\u00adria. It accom\u00adpa\u00adnies inno\u00adva\u00adtive high-tech compa\u00adnies in the Free State through various growth phases, from seed to later stage, with equity capi\u00adtal in the amount of 0.25 to 25 million euros. Bayern Kapi\u00adtal often fills gaps in the VC sector in proven consor\u00adtium constel\u00adla\u00adti\u00adons with private inves\u00adtors (busi\u00adness angels, family offices and corpo\u00adrate ventures).<\/p>\n

Bayern Kapi\u00adtal mana\u00adges specia\u00adli\u00adzed invest\u00adment funds with a volume of around 700 million euros. Since its foun\u00adda\u00adtion in 1995 on the initia\u00adtive of the state govern\u00adment, the wholly owned subsi\u00addiary of LfA F\u00f6rder\u00adbank Bayern has so far inves\u00adted around 400 million euros of its own equity capi\u00adtal in around 300 start-ups and scale-ups in sectors such as life scien\u00adces, soft\u00adware & IT, mate\u00adri\u00adals & new mate\u00adri\u00adals, nano\u00adtech\u00adno\u00adlogy and envi\u00adron\u00admen\u00adtal tech\u00adno\u00adlogy. As a result, more than 8,000 jobs have been perma\u00adnently crea\u00adted in Bava\u00adria in sustainable compa\u00adnies. The active port\u00adfo\u00adlio curr\u00adently compri\u00adses over 80 companies.<\/p>\n

Examp\u00adles of nume\u00adrous ground\u00adbrea\u00adking success stories that Bayern Kapi\u00adtal has been invol\u00adved in at an early stage include EOS (today the worl\u00add\u2019s leading tech\u00adno\u00adlogy provi\u00adder in indus\u00adtrial 3D prin\u00adting of metals and plas\u00adtics), Proglove, Fazua, SimS\u00adcale, Scom\u00adpler, egym, Parcel\u00adlab, Cobrai\u00adner, Quan\u00adtum Systems, Casavi, Riskme\u00adthods, Tubu\u00adlis, Cata\u00adlym, Immu\u00adnic, Sirion, tado and many more.
\nwww.bayernkapital.de<\/a>
\n
\n<\/strong>About mbio\u00admics<\/strong>
\nFoun\u00added in 2020 and head\u00adquar\u00adte\u00adred in Munich, Germany, mbio\u00admics GmbH is a priva\u00adtely held biotech company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of first gene\u00adra\u00adtion effec\u00adtive live bacte\u00adrial thera\u00adpeu\u00adtics (LBT). The company is lever\u00adaging its custom micro\u00adbiome diagno\u00adstics plat\u00adform to over\u00adcome current bott\u00adlen\u00adecks in LBT deve\u00adlo\u00adp\u00adment \u2014 gene\u00adra\u00adting accu\u00adrate profil\u00ading data, selec\u00adting better consor\u00adtia, and impro\u00adving pati\u00adent stra\u00adti\u00adfi\u00adca\u00adtion and moni\u00adto\u00adring in clini\u00adcal trials.
\nwww.mbiomics.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Landshut\/Munich \u2014 Bayern Kapi\u00adtal, one of the most expe\u00adri\u00aden\u00adced and active inves\u00adtors in the high-tech finan\u00adcing land\u00adscape, is inves\u00adt\u00ading in mbio\u00admics GmbH. The Munich-based company is a pioneer in the field of micro\u00adbiome biotech\u00adno\u00adlogy and is deve\u00adlo\u00adping the first gene\u00adra\u00adtion of effec\u00adtive micro\u00ad\u00adbiome-based live thera\u00adpeu\u00adtics (LBT). In addi\u00adtion to Bayern Kapi\u00adtal, MIG Capi\u00adtal as lead [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":48151,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-48153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\nBayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Landshut\/Munich \u2014 Bayern Kapi\u00adtal, one of the most expe\u00adri\u00aden\u00adced and active inves\u00adtors in the high-tech finan\u00adcing land\u00adscape, is inves\u00adt\u00ading in mbio\u00admics GmbH. The Munich-based company is a pioneer in the field of micro\u00adbiome biotech\u00adno\u00adlogy and is deve\u00adlo\u00adping the first gene\u00adra\u00adtion of effec\u00adtive micro\u00adbiome-based live thera\u00adpeu\u00adtics (LBT). In addi\u00adtion to Bayern Kapi\u00adtal, MIG Capi\u00adtal as lead […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-23T17:13:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-23T17:14:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1940\" \/>\n\t<meta property=\"og:image:height\" content=\"1293\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Bayern Kapital invests in mbiomics in Series A round\",\"datePublished\":\"2023-03-23T17:13:38+00:00\",\"dateModified\":\"2023-03-23T17:14:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\"},\"wordCount\":874,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\",\"url\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\",\"name\":\"Bayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg\",\"datePublished\":\"2023-03-23T17:13:38+00:00\",\"dateModified\":\"2023-03-23T17:14:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg\",\"width\":1940,\"height\":1293},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayern Kapital invests in mbiomics in Series A round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/","og_locale":"en_US","og_type":"article","og_title":"Bayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook","og_description":"Landshut\/Munich \u2014 Bayern Kapi\u00adtal, one of the most expe\u00adri\u00aden\u00adced and active inves\u00adtors in the high-tech finan\u00adcing land\u00adscape, is inves\u00adt\u00ading in mbio\u00admics GmbH. The Munich-based company is a pioneer in the field of micro\u00adbiome biotech\u00adno\u00adlogy and is deve\u00adlo\u00adping the first gene\u00adra\u00adtion of effec\u00adtive micro\u00adbiome-based live thera\u00adpeu\u00adtics (LBT). In addi\u00adtion to Bayern Kapi\u00adtal, MIG Capi\u00adtal as lead […]","og_url":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2023-03-23T17:13:38+00:00","article_modified_time":"2023-03-23T17:14:20+00:00","og_image":[{"width":1940,"height":1293,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Bayern Kapital invests in mbiomics in Series A round","datePublished":"2023-03-23T17:13:38+00:00","dateModified":"2023-03-23T17:14:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/"},"wordCount":874,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg","articleSection":["General","Featured","News","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/","url":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/","name":"Bayern Kapital invests in mbiomics in Series A round - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg","datePublished":"2023-03-23T17:13:38+00:00","dateModified":"2023-03-23T17:14:20+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2023\/03\/monika-steger-003-e1679591451264.jpeg","width":1940,"height":1293},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/bayern-kapital-invests-in-mbiomics-in-series-a-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Bayern Kapital invests in mbiomics in Series A round"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/48153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=48153"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/48153\/revisions"}],"predecessor-version":[{"id":48154,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/48153\/revisions\/48154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/48151"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=48153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=48153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=48153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}